Spelling suggestions: "subject:"draft versus most disease"" "subject:"draft versus cost disease""
11 |
Identification of genes regulated in target organs of acute graft versus host disease in different organs in different speciesShah, Pranali Nitin 19 August 2016 (has links)
No description available.
|
12 |
Induktion von GvHD-artigen Gewebeschäden an humanen artifiziellen Hautmodellen / Induction of GvHD-like tissue damage in human artificial skin modelsWallstabe, Julia January 2020 (has links) (PDF)
Graft-versus-Host Disease (GvHD) stellt einen häufigen, den Gesamterfolg einer allogenen hämatopoetischen Stammzelltransplantation limitierenden Faktor dar. Bei dieser Komplikation attackieren vor allem alloreaktive T-Lymphozyten des Stammzellspenders gesunde Körperzellen des Patienten. Infolgedessen kommt es zu Gewebeschäden in den Zielorganen Haut, Leber und Darm. Die Behandlung der GvHD erfordert eine effektive Immunsuppression, was wiederum Graft-versusTumor-Effekte kompromittiert und den Rückfall der malignen Grunderkrankung bedingen kann. Viele Patienten sprechen aus bisher ungeklärten Gründen nicht auf die klassische immunsuppressive Therapie mit Steroiden oder second-line Therapien an. Neue zelluläre Therapien zur Behandlung der refraktären GvHD sind auf dem Vormarsch, bedürfen aber einer weiterführenden klinischen Testung, auch um die exakten Wirkungsmechanismen zu verstehen. Idealerweise könnten neue Testsysteme das GvHD-Potential von allogenen Stammzellpräparaten oder aber das immunsuppressive Potential von neuen GvHD-Therapien vorhersagen, bevor diese in klinischen Studien eingesetzt werden. Ziel der vorliegenden Arbeit war es, ein erstes, in multiplen Replikaten einsetzbares, humanes organotypisches Gewebemodell zur Simulation einer GvHD-Reaktion am Beispiel der Haut zu etablieren.
Zu diesem Zweck wurden artifizielle humane Hautmodelle unter statischen (KollagenHautmodelle) und dynamischen Kulturbedingungen (vaskularisierte Hautmodelle) generiert. Die Injektion unstimulierter PBMCs (engl. peripheral blood mononuclear cells) führte zu keinen histomorphologischen Veränderungen in den KollagenHautmodellen. Im Gegensatz dazu hatte die Injektion vorstimulierter allogener PBMCs eine Zerstörung der epidermalen Strukturen der Kollagen-Hautmodelle zur Folge, welche vergleichbar waren mit Gewebeschäden bei einer akuten GvHD der Haut. Dieselben Schädigungen der Epidermis wurden durch die Injektion von Mediumüberständen vorstimulierter PBMCs in die Kollagen-Hautmodelle erreicht. Im Kulturmedium der Kollagen-Hautmodelle wurden hohe Konzentrationen von Interleukin 2 und 17, Interferon gamma sowie Tumornekrosefaktor alpha gemessen, wodurch auf die Beteiligung von Zytokinen an der inflammatorischen Reaktion geschlossen werden konnte. Auch im komplexeren vaskularisierten Hautmodell verursachte die Injektion vorstimulierter PBMCs histomorphologische Veränderungen entsprechend einer akuten Haut-GvHD sowie einen zeitabhängigen Anstieg proinflammatorischer Zytokine.
Zusammenfassend zeigen die Resultate dieser Arbeit, dass die Induktion einer starken Inflammations- und Immunreaktion in artifiziellen humanen Hautmodellen, welche histomorphologisch eine GvHD imitiert, möglich ist. Dieses Modell könnte als Grundlage für die Entwicklung eines klinisch relevanten Testsystems zur Bestimmung des GvHD-Restpotentials oder zur Festlegung der immunsuppressiven Kapazität innovativer Zellpräparate dienen. Somit könnten humane artifizielle GvHDModelle in klinischen Studien eingesetzt werden und die Erfahrungen aus Tiermodellen ergänzen sowie erste in vitro Ergebnisse im humanen System liefern, welche dann mit dem tatsächlichen klinischen Resultat verglichen werden könnten. / Graft-versus-Host Disease (GvHD) remains the most important limiting factor for the success of allogeneic hematopoietic stem cell transplantation. This major complication is caused by alloreactive donor T-lymphocytes that attack healthy tissues of the recipient leading to severe tissue damage within the target organs skin, liver and gut. Treatment of GvHD requires effective immunosuppression, which in turn impairs Graft-versus-Tumor activity and enhances the risk for relapse of the malignant disease. However, for still unknown reasons many patients do not respond to standard immunosuppressive therapy with steroids or to second-line therapies. Development of novel cellular therapies that gain more and more clinical relevance due to their high anti-tumor potency lead to a strong demand for advanced test platforms to further investigate their underlying functional mechanisms and exclude off-tumor effects against healthy tissues. Ideally, new test systems could be used for the prediction of the GvHD potential of allogeneic stem cell products or for prediction of an immunosuppressive potential of novel GvHD therapies before entering clinical studies. The aim of this study was to establish a GvHD test system based on human organotypic skin models allowing the simulation of GvHD reactions in the skin in multiple replicates.
To this end, artificial human skin models were generated under static (collagen skin model) and dynamic culture conditions (vascularized skin model). Injection of unstimulated peripheral blood mononuclear cells (PBMCs) did not cause histomorphological changes in collagen skin models. In contrast, injection of prestimulated PBMCs resulted in disruption of the epidermis of collagen skin models mimicking acute skin GvHD. The same disruption of the epidermal layer was observed using cell culture supernatants of prestimulated PBMCs, suggesting the involvement of proinflammatory cytokines. Indeed, measurement of cytokine levels in culture supernatants revealed an increase of interleukin 2 and 17, interferon gamma and tumor necrosis factor alpha. In addition, injection of prestimulated PBMCs into more complex vascularized skin models also caused disruption of the epidermal layer and an increase of proinflammatory cytokine levels in a time dependent manner.
Taken together, these findings demonstrate that it is possible to induce a strong immune reaction and inflammatory tissue damage in artificial human skin models mimicking histomorphological patterns of acute skin GvHD. Therefore, this model could contribute to the development of a clinically relevant GvHD test platform for prediction of the GvHD potential or immunosuppressive capacity of innovative cell products. Thus, artificial human GvHD models may be employed in clinical studies in order to gain first in vitro results in a human system and to extend information from animal models, which can then be compared to the actual clinical outcome.
|
13 |
Migration of allogenic T cells in intestinal lymphoid structures during acute Graft-versus-Host Disease / Migration allogener T-Zellen in intestinalen lymphoiden Strukturen während der akuten Graft-versus-Host ReaktionJarick [née Ottmüller], Katja Julika January 2020 (has links) (PDF)
T cell infiltration into the intestine occurs after priming and activation in the mesenteric lymph nodes and Peyer’s patches and subsequent trafficking via the blood circulation. We hypothesized that additionally to the vascular trafficking route, a fraction of T cells in the Peyer’s patches directly migrate into the adjacent lamina propria of the small intestine. To test this hypothesis, we employed a mouse model of acute Graft-versus-Host Disease to study the direct T cell migration from the Peyer’s patches to the adjacent lamina propria.
First, we analyzed the border of Peyer’s patches on histological sections and found that the Peyer’s patch is not enclosed by a capsule or basement membrane. Thus, the tissue architecture allows for direct access to the surrounding tissue. With whole-mount light sheet fluorescence microscopy we quantified a three-dimensional gradient of T cells around Peyer’s patches on day 2.5 and day 3 after transplantation. This gradient evened out at day 4 and day 6 when high numbers of T cells started to evenly infiltrate the intestine from the blood circulation. We confirmed that gradient-forming T cells around Peyer’s patches resided within the tissue parenchyma of the lamina propria and not inside lymphatic vessels.
To positively prove that the recently activated donor T cells around Peyer’s patches have egressed directly from that patch, we established a protocol for intravital photoconversion of T cells inside Peyer’s patches. 12 h after photoconversion inside a single Peyer’s patch, photoconverted T cells resided only around this particular Peyer’s patch and not elsewhere in the small intestine. This indicated that the T cells did not infiltrate via the blood but migrated to the adjacent lamina propria of the small intestine. Dynamic intravital two-photon microscopy revealed that these T cells next to the Peyer’s patch migrated in a random pattern. This suggested that these cells did not follow a positive chemoattractive gradient once they had reached the lamina propria. Laser-capture microdissection combined with RNA sequencing of the mucosa near the Peyer’s patch identified a wide range of migration-promoting factors. These included chemokines, co-stimulatory receptors and migration-associated intracellular molecules, which are candidates to promote this direct migration from Peyer’s patches.
Altogether, we demonstrate for the first time that additionally to the vascular trafficking route, a fraction of T cells migrates directly from the Peyer’s patch to the surrounding mucosa. This mechanism implies so far unrecognized regional specification of Peyer’s-patch-primed T cells. Our findings may impact treatment strategies to avoid intestinal inflammation or foster immunity after oral vaccination. / T-Zell Infiltration in den Darm erfolgt nach Primen und Aktivierung in den mesenterialen Lymphknoten und Peyerschen Plaques durch Rezirkulation über die Blutbahn. Wir stellten die Hypothese auf, dass zusätzlich zur vaskulären Route ein Teil der T-Zellen im Peyerschen Plaque direkt in die angrenzende Lamina propria des Dünndarms wandert. Um diese Hypothese zu testen, setzten wir ein Mausmodell für eine akute Graft-versus-Host Reaktion ein, um die direkte Migration von T Zellen aus den Peyerschen Plaques in die angrenzende Lamina propria zu untersuchen.
Zuerst analysierten wir die Randzonen um die Peyerschen Plaques mit histologischen Schnitten und konnten bestätigen, dass der Peyersche Plaque von keiner Kapsel oder Basalmembran umschlossen ist, sodass die Gewebearchitektur den direkten Zugang des umliegenden Gewebes zulässt. Mithilfe der Lichtblatt-Fluoreszenzmikroskopie von Dünndarm-Komplettpräparaten quantifizierten wir einen dreidimensionalen T-Zell Gradienten um Peyersche Plaques an den Tagen 2,5 und 3 nach allogener Stammzelltransplantation. Dieser Gradient verschwand zwischen an Tag 4 und Tag 6, als eine hohe Anzahl an T-Zellen begann, den Darm gleichmäßig über die Blutbahn zu infiltrieren. Wir bestätigten, dass die Gradienten-bildenden T-Zellen im Gewebe der Lamina propria und nicht in lymphatischen Gefäßen saßen, um zirkulierende Zellen von der Gradientenbildung auszuschließen.
Um direkt zu beweisen, dass die T-Zellen um dem Peyerschen Plaque unmittelbar aus diesem Plaque ausgewandert sind, haben wir ein Protokoll für intravitale Photokonversion von T-Zellen im Peyerschen Plaque etabliert. 12 h nach der Photokonversion in einem einzelnen Peyerschen Plaque befanden sich die T-Zellen nur um diesen bestimmten Plaque herum. Dies zeigt, dass die T-Zellen das Gewebe nicht über die Blutbahn infiltrierten, sondern direkt in die angrenzende Lamina propria des Dünndarms gewandert waren. Dynamische intravitale Zweiphotonenmikrokopie offenbarte, dass diese T-Zellen um den Peyerschen Plaque nach zufälligem Schema wanderten. Dies legte nahe, dass diese T-Zellen keinem positiven Chemokingradienten folgten, sobald sie die Lamina propria erreicht hatten. Laser-Mikrodissektion kombiniert mit RNA-Sequenzierung der Mukosa nahe des Peyerschen Plaques identifizierte eine große Auswahl an migrationsfördernden Faktoren. Hierunter waren Chemokine, kostimulatorische Rezeptoren und intrazelluläre migrationsassoziierte Moleküle, welche Kandidaten sind, diese direkte Migration aus den Peyerschen Plaques zu fördern.
In dieser Arbeit zeigen wir erstmalig, dass zusätzlich zur vaskulären Route ein Teil der T Zellen direkt vom Peyerschen Plaque in die umliegende Mukosa wandert. Dieser Mechanismus impliziert bislang unerkannte regionale Spezialisierung von T Zellen, welche in Peyerschen Plaques aktiviert wurden. Diese neuen Befunde können zukünftige Behandlungsstrategien gegen intestinale Entzündungserkrankungen oder für Immunreaktionen nach oraler Impfung beeinflussen.
|
14 |
Einfluss der Zytokingenpolymorphismen bei allogen transplantierten Kindern auf das Vorliegen einer Graft-versus-Host-Disease / Influence of cytokine polymorphisms in allogeneic transplanted children on the presence of graft-versus-host diseaseRasche, Engelke Kristina January 2019 (has links) (PDF)
Im Rahmen dieser Arbeit wurden 72 pädiatrische Patienten, die eine allogene Stammzelltransplantation erhielten, auf die Spender- und Empfänger-Zytokinpolymorphismen TNF-α, TGF-β1, IL-10, IL-6 und IFN-γ untersucht. Die Proben wurden mittels DNA-Extraktion, sequenzspezifischer PCR und Gelelektrophorese analysiert und auf deren Einfluss auf die Entstehung und den Verlauf maligner Erkrankungen sowie auf die Entstehung einer GvHD untersucht. / Within the scope of this work, 72 pediatric patients who received allogeneic stem cell transplantations were examined for the donor and recipient cytokine polymorphisms TNF-α, TGF-β1, IL-10, IL-6 and IFN-γ. We analyzed the samples by means of DNA extraction, sequence-specific PCR and gel electrophoresis and investigated their influence on the development and course of malignant diseases as well as on the development of a GvHD.
|
15 |
The immunobiology and clinical management of acute graft versus host disease after allogeneic transplantChen, Kaina 31 January 2023 (has links)
Alloreactivity between donor cells against disparate host tissue is a natural and normal physiologic phenomenon after engraftment. Consequently, GVHD is a universally expected side effect after allogeneic HSCT. An effective strategy to prevent severe or fatal acute GVHD is require if the transplant is to be successful.
The HSCT field has witnessed significant progress in the prevention and treatment of acute GVHD. However, select interventions come at the cost of losing the alloimmune activity that prevents relapse, the GVL effect, as many of the mechanisms which cause GVHD are shared with those responsible for GVL. Current efforts are focused on therapeutic interventions that not only alleviate the burden of acute GVHD but does so in a way that maintains the GVL effect.
This review will provide an up-to-date overview of our current understanding of the diagnosis, risk stratification, immunobiology of acute GVHD, summarize efforts to prevent and treat the disease, and provide a perspective on future directions.
|
16 |
Interleukin-15: biology, pathophysiology, and pre-clinical application in diseaseRoychowdhury, Sameek 20 July 2004 (has links)
No description available.
|
17 |
New approaches to improve Extracorporeal Photopheresis for the treatment of Graft-versus-Host DiseasePapert, Susanne 09 May 2016 (has links)
No description available.
|
18 |
Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantationStokes, Jessica, Hoffman, Emely A., Zeng, Yi, Larmonier, Nicolas, Katsanis, Emmanuel 07 1900 (has links)
Advances in haploidentical bone marrow transplantation (h-BMT) have drastically broadened the treatment options for patients requiring BMT. The possibility of significantly reducing the complications resulting from graft-versus-host disease (GvHD) with the administration of post-transplant cyclophosphamide (PT-CY) has substantially improved the efficacy and applicability of T cell-replete h-BMT. However, higher frequency of disease recurrence remains a major challenge in h-BMT with PT-CY. There is a critical need to identify novel strategies to prevent GvHD while sparing the graft-versus-leukaemia (GvL) effect in h-BMT. To this end, we evaluated the impact of bendamustine (BEN), given post-transplant, on GvHD and GvL using clinically relevant murine h-BMT models. We provide results indicating that post-transplant bendamustine (PT-BEN) alleviates GvHD, significantly improving survival, while preserving engraftment and GvL effects. We further document that PT-BEN can mitigate GvHD even in the absence of Treg. Our results also indicate that PT-BEN is less myelo-suppressive than PT-CY, significantly increasing the number and proportion of CD11b(+)Gr-1(hi) cells, while decreasing lymphoid cells. In vitro we observed that BEN enhances the suppressive function of myeloid-derived suppressor cells (MDSCs) while impairing the proliferation of T-and B-cells. These results advocate for the consideration of PT-BEN as a new therapeutic platform for clinical implementation in h-BMT.
|
19 |
DISTINCT T CELL CLONES ARE ASSOCIATED WITH GRAFT-VERSUS-HOST DISEASE (GVHD), AND POTENTIALLY GRAFT-VERSUS-TUMOR (GVT), RESPONSES FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATIONBerrie, Jennifer 28 April 2011 (has links)
In patients undergoing hematopoietic stem cell transplantation (HSCT) with HLA-identical donors, genetic polymorphisms result in a mismatch between donors and recipients in their minor histocompatibility antigens (mHAgs), and tumors may also express tumor-associated antigens (TAA) that may not be abundantly present in the donors. Donor T cells can recognize such mHAgs and TAAs as foreign antigens and generate an objective response against hematologic malignancies in a graft-versus-tumor (GVT) effect. However, a major side effect of HSCT occurs when donor T cells are alloreactive against the recipients’ normal cells, leading to graft-versus-host disease (GVHD). The ability to identify T cell clones that are exclusively involved in the GVT or GVHD responses remains elusive. In this study, we looked at clonally-driven CD3+ T cells in patients with hematologic malignancies prior to and after transplantation. We identified Vbeta families of increased expression involved in GVHD or GVT responses, with Vbetas 4, 11, and 23 being associated with GVHD, Vbetas 9, 16, and 20 being associated with GVT, and Vbetas 2, 3, 7, 8, 12, 15, and 17 being involved in GVHD and/or GVT. We were also able to identify some of the Vbeta families that were increased in the peripheral blood at the site of GVHD. Furthermore, one of our twelve patients had donor lymphocyte infusions (DLIs) for treatment of relapse, from which we were able to observe oligoclonal T cells that emerged at the time of post-DLI remission and re-establishment of GVHD.
|
20 |
Generation and characteriztion of regulatory dendritic cells for the amelioration of acute graft versus host diseaseScroggins, Sabrina Marie 01 December 2013 (has links)
Despite Human Leukocyte Antigen (HLA) matching and use of immunosuppressive drugs, graft-versus-host disease (GVHD) following hematopoietic stem cell transplant (HSCT) is prevalent and often fatal. Additionally, older HSCT recipients experience increased morbidity and mortality. Prophylactic treatment with age-matched syngeneic (recipient strain-derived) cultured regulatory DC (DCreg) has been shown to decrease GVHD-associated mortality in young bone marrow transplanted (BMT) mice. The purpose of this study was to investigate: 1) the potential to generate DCreg from older mice and their subsequent ability to ameliorate GVHD in older BMT mice, 2) the mechanism(s) by which DCreg mitigate GVHD in vivo, 3) the ability of DCreg-treated BMT mice to respond to infectious pathogens, and 4) whether DCreg can be generated under clinically relevant conditions from healthy donor and HSCT recipient PBMCs.
To evaluate the efficacy of DCreg treatment in older mice, complete MHC-mismatched BMT mice were treated with DCreg (hereafter referred to as DCreg-treated BMT mice). Although DCreg treatment ameliorated GVHD in older BMT mice, these mice had increased morbidity and decreased survival compared to their young counterparts.
Following transfer into BMT mice, older DCreg failed to increase inhibitory molecule (PD-L1 and PIR B) expression while significantly upregulating co-stimulatory molecule (CD40 and CD80) expression, conversely young DCreg upregulated inhibitory molecules as well as co-stimulatory molecules. These phenotypic differences between young and older DCreg in vivo provide a potential mechanism for modestly increased morbidity and mortality in older DCreg-treated BMT mice relative to their young counterparts. Indeed, BMT mice treated with DCreg deficient in PD-L1 or PIR B had significantly reduced overall survival, thus both molecules are required for optimal GVHD mitigation.
A murine H1N1 influenza (IAV) infection model was used to assess the donor immune system's capacity to respond to relevant antigens other than those responsible for GVHD. Surprisingly, sub-lethally IAV-infected DCreg-treated BMT mice began to die after d. +21 and all were deceased by d. +25. Virus-specific CD8+ T cell and antibody (Ab) responses were undetectable following primary infection. Interestingly, following a prime-boost infection strategy, DCreg-treated BMT mice survived lethal IAV challenge with no signs of morbidity and had demonstrable IAV-specific Ab and CD8+ T cell responses. Thus a prime-boost IAV infection strategy establishes a protective immune response in the DCreg-treated BMT mice and underscores the potential role vaccination may play in establishing immune competence in DCreg-treated BMT mice.
We investigated whether human DCreg can be generated under clinically relevant conditions: 1) following peripheral blood mononuclear cell (PBMC) cryopreservation, 2) in bovine serum-free media, and 3) from older individuals and HSCT recipients. DCreg were generated from healthy donor and HSCT patient PBMCs isolated from young (old) and older (> 50 years old) individuals by culturing cells in X-vivo serum-free.
Human DCreg generated from both young and older healthy donor PBMCs had comparable numbers, surface molecule phenotype, cytokine production, and able to induce Treg. Cryopreserved and fresh PBMCs generated DCreg with similar phenotypes and cytokine production. DCreg generated from HSCT recipients maintained low co-stimulatory molecule and high inhibitory molecule expression as well as immunosuppressive cytokine production. These studies confirm DCreg can be generated under clinically relevant conditions.
|
Page generated in 0.1054 seconds